Product Images Memantine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 15 images provide visual information about the product associated with Memantine NDC 60687-184 by American Health Packaging, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
10 mg Blister
This is information related to Memantine Hydrochloride tablets in various doses of 10mg and the text contains the drug name, Tablet, and some identifying numbers of the drug.*
10 mg Carton
This is a description of a drug named "Memantine Hydrochloride". Each package contains 60 tablets of size 6 x 10. The drug contains 10mg of Hiermantne hyorochiorde USP. The usual dosage information is provided with the package insert. The drug should be stored between 20° to 25°C. The package is distributed by American Geaih Pagaing.*
5 mg Blister
This is a list of different types of tablets of Memantine Hydrochloride at different dosages (5mg and smg) and under different names (Memanting, Wemarting, Wamanine, Wemaniine, Vemaripepcoctioride). It also includes batch and expiry information on some of the tablets.*
5 mg Carton
The text is a description of a medication called Memantine Hydrochloride in tablet form. The medication comes in a pack of 60 tablets and can only be obtained with a prescription. The pharmacist is advised to dispense the accompanying patient information sheet to each patient. The rest of the text is not readable.*
883dccf8 44b2 5f82 e053 2995a90a12dd
883dccf8 44b3 5f82 e053 2995a90a12dd
Memantine HCl Structural Formula - image 01 01
Figure 1: Time course of the change from baseline in ADCS-ADL score for patients completing 28 weeks of treatment. - image 02 01
Figure 2: Cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. - image 03 01
Figure 3: Time course of the change from baseline in SIB score for patients completing 28 weeks of treatment. - image 04 01
Figure 4: Cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in SIB scores. - image 05 01
Figure 5: Time course of the change from baseline in ADCS-ADL score for patients completing 24 weeks of treatment. - image 06 01
Figure 6: Cumulative percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. - image 07 01
Figure 7: Time course of the change from baseline in SIB score for patients completing 24 weeks of treatment. - image 08 01
Figure 8: Cumulative percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in SIB scores. - image 09 01
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.